A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
An open-label Phase I/II study, with a dose escalation part (Phase I) and a 2-arm randomized part (Phase II), in patients with recurrent SCLC.
Read MorePneumothorax Helps Improve CT Scans, Early Detection for Mesothelioma Patients
Diagnosing mesothelioma in the early stages of the disease has proven to be a difficult task, and to better improve chances of survival from this aggressive cancer, the cancer needs to be found and treated quickly. Typical first steps in diagnosing mesothelioma are imaging techniques such as an x-ray, CT (CAT) scan, or an MRI.…
Read MoreHybrid APC Therapy in Early Central Lung Cancer
This cohort study aims to investigate the clinical value of Hybrid APC for treatment of early central lung cancer.
Read MoreWhy is Chemotherapy Often Ineffective in Those Suffering from Mesothelioma?
Mesothelioma is a difficult cancer to treat for a multitude of reasons. A mesothelioma diagnosis is rare – only about 3,000 people per year in the United States are diagnosed – and this can make it difficult to study, given that there is generally a very small sample of patients that are able to be…
Read MoreAssociation Between Proton Pump Inhibitors and Hematologic Toxicity of Pemetrexed (IPPEM)
Pemetrexed is a multi-folate inhibitor approved in the treatment of non-small cell lung cancer (NSCLC) and pleural mesothelioma. Its toxicity profile is mainly hematologic (anemia, neutropenia and thrombopenia) and can be limiting when > grade 2 according to NCI-CTCAE criteria. First clinical trials highlighted hematologic toxicity, especially anemia, which was reduced by decreasing pemetrexed dosage from 600 to 500 mg/m² Q3W and by adding systematic vitamin supplementation (B9/B12). Despite this, incidence of hematological toxicity remains frequent with anemia occurring in more than 20% of patients treated by pemetrexed in combination. The investigators aim to investigate the potential association between PPIs and pemetrexed combination and the incidence of hematological toxicity in a multicenter and prospective study.
Read MoreNintedanib May Surpass Bevacizumab as a More Effective Chemotherapy Treatment for Mesothelioma
In 2016, scientists and researchers were excited to begin Phase II of the clinical trial involving treating patients with malignant pleural mesothelioma with Nintedanib, a triple angiokinase inhibitor designed to hinder protein kinases in cancer cells and stop cancer cells from growing their own blood vessels. The LUME-Meso Phase II trial yielded promising results –…
Read MoreM7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers
To determine the efficacy of M7824 plus topotecan or temozolomide in relapsed SCLC.
Read MoreEPA Proposes New Rules For Asbestos; Anti-Asbestos Advocates Concerned
In June 2016, former President Obama signed the Frank R. Lautenberg Chemical Safety for the 21st Century Act as an amendment to the Toxic Substances Control Act (TSCA), and since then, the Environmental Protection Agency (EPA) has been moving forward in naming asbestos – as well as nine other chemicals – as toxic substances that…
Read MorePembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients With PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies (MESOVAX)
Purpose: Pembrolizumab plus autologous dendritic cell vaccine in patients with PD-L1 negative advanced mesothelioma who have failed prior therapies.This is an exploratory, single-arm, open-label, phase 1b clinical trial.
Read MoreUpdated Modified RECIST to Better Evaluate Treatment Response in Mesothelioma
The Response Evaluation Criteria in Solid Tumors (RECIST) was established nearly two decades ago by the European Organization for Research and Treatment of Cancer and the National Cancer Institute of the United States. The purpose of these published rules was to universally define when cancerous tumors stabilize, progress, or just respond to any given treatment.…
Read More